PURPOSE: We created an evidence based postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma (RCC) based on a risk group stratification system. MATERIALS AND METHODS: 559 patients undergoing surgery for localized and ocally advanced RCC were stratified into low risk (LR), intermediate risk (IR) and high risk (HR) groups based on the University of California-Los Angeles Integrated Staging System (UISS). Tumor recurrences were identified and categorized according to time and location. RESULTS: Patients with localized disease had a lower 5-year recurrence rate than patients with locally advanced (nodal) disease (27.6% vs 64%, p <0.0001). Patients in the LR, IR, and HR groups following nephrectomy demonstrated 5-year recurrence-free rates of 90.4%, 61.8%, and 41.9%, respectively (p <0.0001), and median times to recurrence of 28.9, 17.8 and 9.5 months, respectively (p <0.0001). Chest and abdomen recurrences comprised of 75% and 37.5%, 77.4% and 58.1%, and 45.2% and 67.7% of recurrences in the LR, IR and HR groups, respectively. In patients with node positive disease, chest and abdomen comprised of 58.8% and 76.5% of recurrences, respectively. Patients undergoing partial nephrectomy did not demonstrate a greater rate of local or distant recurrence compared with patients undergoing radical nephrectomy. CONCLUSIONS: Significant differences in incidence and time to recurrence following surgical resection for RCC mandates unique surveillance protocols for patients in each of the UISS risk groups. LR group patients should be followed for at least 5 years, whereas IR and HR group patients require longer surveillance. HR group patients require more stringent abdominal surveillance, whereas LR group patients should emphasize the chest. Patients with nodal disease also require stringent followup. Patients undergoing partial nephrectomy for localized disease can be followed according to the same UISS risk group based protocol.
PURPOSE: We created an evidence based postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma (RCC) based on a risk group stratification system. MATERIALS AND METHODS: 559 patients undergoing surgery for localized and ocally advanced RCC were stratified into low risk (LR), intermediate risk (IR) and high risk (HR) groups based on the University of California-Los Angeles Integrated Staging System (UISS). Tumor recurrences were identified and categorized according to time and location. RESULTS:Patients with localized disease had a lower 5-year recurrence rate than patients with locally advanced (nodal) disease (27.6% vs 64%, p <0.0001). Patients in the LR, IR, and HR groups following nephrectomy demonstrated 5-year recurrence-free rates of 90.4%, 61.8%, and 41.9%, respectively (p <0.0001), and median times to recurrence of 28.9, 17.8 and 9.5 months, respectively (p <0.0001). Chest and abdomen recurrences comprised of 75% and 37.5%, 77.4% and 58.1%, and 45.2% and 67.7% of recurrences in the LR, IR and HR groups, respectively. In patients with node positive disease, chest and abdomen comprised of 58.8% and 76.5% of recurrences, respectively. Patients undergoing partial nephrectomy did not demonstrate a greater rate of local or distant recurrence compared with patients undergoing radical nephrectomy. CONCLUSIONS: Significant differences in incidence and time to recurrence following surgical resection for RCC mandates unique surveillance protocols for patients in each of the UISS risk groups. LR group patients should be followed for at least 5 years, whereas IR and HR group patients require longer surveillance. HR group patients require more stringent abdominal surveillance, whereas LR group patients should emphasize the chest. Patients with nodal disease also require stringent followup. Patients undergoing partial nephrectomy for localized disease can be followed according to the same UISS risk group based protocol.
Authors: A Rose Brannon; Anupama Reddy; Michael Seiler; Alexandra Arreola; Dominic T Moore; Raj S Pruthi; Eric M Wallen; Matthew E Nielsen; Huiqing Liu; Katherine L Nathanson; Börje Ljungberg; Hongjuan Zhao; James D Brooks; Shridar Ganesan; Gyan Bhanot; W Kimryn Rathmell Journal: Genes Cancer Date: 2010-02-01
Authors: Daniel J George; Jean-Francois Martini; Michael Staehler; Robert J Motzer; Ahmed Magheli; Frede Donskov; Bernard Escudier; Sherry Li; Michelle Casey; Olga Valota; Brigitte Laguerre; Allan J Pantuck; Hardev S Pandha; Anup Patel; Maria Lechuga; Alain Ravaud Journal: Clin Cancer Res Date: 2018-11-06 Impact factor: 12.531
Authors: Ganesh V Raj; R Houston Thompson; Bradley C Leibovich; Michael L Blute; Paul Russo; Michael W Kattan Journal: J Urol Date: 2008-04-18 Impact factor: 7.450
Authors: Y A M Kuijpers; R P Meijer; G N Jonges; J de Jong; J L H R Bosch; S Horenblas; A Bex Journal: World J Urol Date: 2016-04-07 Impact factor: 4.226
Authors: Robert J Motzer; Naomi B Haas; Frede Donskov; Marine Gross-Goupil; Sergei Varlamov; Evgeny Kopyltsov; Jae Lyun Lee; Bohuslav Melichar; Brian I Rini; Toni K Choueiri; Milada Zemanova; Lori A Wood; M Neil Reaume; Arnulf Stenzl; Simon Chowdhury; Ho Yeong Lim; Ray McDermott; Agnieszka Michael; Weichao Bao; Marlene J Carrasco-Alfonso; Paola Aimone; Maurizio Voi; Christian Doehn; Paul Russo; Cora N Sternberg Journal: J Clin Oncol Date: 2017-09-13 Impact factor: 44.544